Purpose
|
Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.
|
Characteristics
|
Tradename: Bay 43-9006 Source of Compound: synthetic Target: PDGFR inhibitor, Raf inhibitor, FLT3 inhibitor, FGFR inhibitor, RET inhibitor, Mast/stem cell GFR Kit Receptor: PDGFRβ, B-raf, RAF-1, FLT3, Mast/stem cell GFR, FGFR1, ret,Mast/stem cell GFR Kit
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
99?%
|
Formula
|
C21H16ClF3N4O3.C7H8O3S
|
Solubility
|
DMSO 127 mg/mL,Water <1 mg="" ml="" <="" td="">
1> |